Loading...
Loading...
DVAX| Name | Value |
|---|---|
| Revenues | 80.6M |
| Cost of Revenue | 13.1M |
| Gross Profit | 67.5M |
| Operating Expense | 57.5M |
| Operating I/L | 10.1M |
| Other Income/Expense | 9.7M |
| Interest Income | 9.4M |
| Pretax | 19.8M |
| Income Tax Expense | 2.2M |
| Net Income/Loss | 17.6M |
Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of vaccines. Its flagship product, HEPLISAV-B, is a hepatitis B vaccine designed to prevent infection caused by all known subtypes of hepatitis B virus in individuals aged 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation generates revenue through the sale of its vaccines and adjuvant, as well as through collaboration and sublicense agreements with other pharmaceutical companies.
